Taiwan
· Delayed Price · Currency is TWD TaiMed Biologics Statistics
Total Valuation
TaiMed Biologics has a market cap or net worth of TWD 21.81 billion. The enterprise value is 20.21 billion.
| Market Cap | 21.81B |
| Enterprise Value | 20.21B |
Important Dates
The next estimated earnings date is Tuesday, November 12, 2024.
| Earnings Date | Nov 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
TaiMed Biologics has 273.01 million shares outstanding. The number of shares has increased by 2.22% in one year.
| Shares Outstanding | 273.01M |
| Shares Change (YoY) | +2.22% |
| Shares Change (QoQ) | +7.73% |
| Owned by Insiders (%) | 1.46% |
| Owned by Institutions (%) | 5.29% |
| Float | 185.52M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 49.02 |
| PS Ratio | 32.14 |
| PB Ratio | 5.21 |
| P/FCF Ratio | 188.86 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -184.13 |
| EV / Sales | 31.49 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 174.94 |
Financial Position
The company has a current ratio of 25.38, with a Debt / Equity ratio of 12.82.
| Current Ratio | 25.38 |
| Quick Ratio | 16.56 |
| Debt / Equity | 12.82 |
| Debt / EBITDA | 12.78 |
| Debt / FCF | 4.65 |
| Interest Coverage | -7.65 |
Financial Efficiency
Return on equity (ROE) is -3.21% and return on invested capital (ROIC) is -1.66%.
| Return on Equity (ROE) | -3.21% |
| Return on Assets (ROA) | -1.46% |
| Return on Capital (ROIC) | -1.66% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.14 |
| Inventory Turnover | 0.29 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -13.25% in the last 52 weeks. The beta is 0.35, so TaiMed Biologics's price volatility has been lower than the market average.
| Beta (5Y) | 0.35 |
| 52-Week Price Change | -13.25% |
| 50-Day Moving Average | 82.03 |
| 200-Day Moving Average | 86.68 |
| Relative Strength Index (RSI) | 43.81 |
| Average Volume (20 Days) | 628,302 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, TaiMed Biologics had revenue of TWD 641.66 million and -109.74 million in losses. Loss per share was -0.43.
| Revenue | 641.66M |
| Gross Profit | 272.57M |
| Operating Income | -108.09M |
| Pretax Income | -109.74M |
| Net Income | -109.74M |
| EBITDA | 39.78M |
| EBIT | -108.09M |
| Loss Per Share | -0.43 |
Balance Sheet
The company has 2.14 billion in cash and 537.15 million in debt, giving a net cash position of 1.61 billion or 5.89 per share.
| Cash & Cash Equivalents | 2.14B |
| Total Debt | 537.15M |
| Net Cash | 1.61B |
| Net Cash Per Share | 5.89 |
| Equity (Book Value) | 4.19B |
| Book Value Per Share | 15.34 |
| Working Capital | 3.43B |
Cash Flow
In the last 12 months, operating cash flow was 119.88 million and capital expenditures -4.38 million, giving a free cash flow of 115.50 million.
| Operating Cash Flow | 119.88M |
| Capital Expenditures | -4.38M |
| Free Cash Flow | 115.50M |
| FCF Per Share | 0.42 |
Margins
Gross margin is 42.48%, with operating and profit margins of -16.85% and -17.10%.
| Gross Margin | 42.48% |
| Operating Margin | -16.85% |
| Pretax Margin | -17.10% |
| Profit Margin | -17.10% |
| EBITDA Margin | 6.20% |
| EBIT Margin | -16.85% |
| FCF Margin | 18.00% |
Dividends & Yields
TaiMed Biologics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.22% |
| Shareholder Yield | -2.22% |
| Earnings Yield | -0.54% |
| FCF Yield | 0.53% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |